Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune test may boost IVF birth rates, study suggests

NCT ID NCT07449494

Knowledge-focused Sponsor: Hopital Pierre Rouques - Les Bluets Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 148 infertile women with an overactive immune system in the uterus who were undergoing IVF. Some women had a test to see if they would respond to steroid treatment before embryo transfer, while others did not. The goal was to see if the test helped improve the chance of a live birth. The study only observed what happened in routine care, without assigning treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

148 people

The number who actually took part.

Started

Sep 2020

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of infertile women aged 40 years or younger undergoing in vitro fertilization (IVF) with a planned fresh or frozen blastocyst transfer at Hôpital Pierre Rouquès - Les Bluets (Paris, France). All patients had documented uterine immune overactivation identified through routine immune assessment prior to embryo transfer. Patients were managed according to standard clinical practice, with first-line glucocorticoid therapy, with or without prior glucocorticoid sensitivity testing.

Ages

Up to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Infertile patients undergoing IVF with planned fresh or frozen embryo transfer * Age ≤ 40 years at the time of the transfer * Documented uterine immune over-activation * Treatment with glucocorticoids in routine clinical practice, with or without prior glucocorticoid sensitivity testing * Fresh or frozen blastocyst transfer performed within 9 months following immune assessment at Hôpital des Bluets Exclusion Criteria: * • Age \> 40 years * No available uterine immune profile * Normal immune profile or immune underactivation * Management exclusively with alternative therapeutic strategies (e.g., low molecular weight heparin \[LMWH\], intralipid therapy) or combination therapies (e.g., LMWH + glucocorticoids or intralipid + glucocorticoids) * Embryo transfer performed more than 9 months after immune assessment * Cleavage-stage embryo transfer * Embryo transfer performed in another center * Oocyte donation IVF cycles

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infertility are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility

Contacts and locations

Locations

  • Hôpital Pierre Rouquès - Les Bluets

    Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.